AstraZeneca, a global pharmaceutical company, has recently launched a new health-tech business called Evinova. This venture will leverage the company’s expertise in clinical trial design and study delivery to offer solutions at scale to trial sponsors, clinical research organizations, care teams, and patients.

Evinova’s offerings include advanced data collection methods and machine learning algorithms to support teams in designing their studies. The goal is to reduce the time and cost of developing new medicines, bring care closer to home for patients, and lessen the burden on healthcare systems. The company has announced major collaborations with Parexel and Fortrea to expand the reach of Evinova’s digital health solutions to a wider customer base.

AstraZeneca’s CEO, Pascal Soriot, expressed confidence in Evinova’s potential to make a significant impact on patient care, healthcare transformation, and carbon emissions reduction. The company also highlighted the expected growth of the digital health market, projected to be worth more than $900 billion by 2032.

For more information on Evinova or AstraZeneca’s digital health initiatives, please contact Michael Susin at michael.susin@wsj.com